Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.

In today’s fast-paced world, maintaining optimal nerve health is paramount for overall well-being. Nerve-related issues can ...

Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers ...

In an era where health and wellness are prioritized more than ever, the quest for effective natural remedies has led many to ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.